Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Areplivir in hospitalized COVID-19 patients
NCT04542694Phase 3Completed
- Sponsor
- Promomed
- Start
- May 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Favipiravir with Standard of Care (2 arms). Primary endpoints: Rate of Clinical Status Improvement at 10 days and Time to Clinical Improvement at 28 days. Started May 2020; status: completed.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04542694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04542694.